1 |
NCT00428519 |
Effects of treatment with aprepitant (Emend_) in
HIV-infected individuals |
I |
2 |
NCT00835965 |
Oral aprepitant and lower dose dexamethasone versus
aprepitant alone for preventing postoperative nausea and vomiting (PONV)
after elective laparoscopic surgeries |
IV |
3 |
NCT00738621 |
Combination antiemetic regimen for prevention of PONV
in breast surgery |
IV |
4 |
NCT00717054 |
Comparison of oral aprepitant alone versus oral
aprepitant and transdermal scopolamine for preventing postoperative
nausea and vomiting |
III |
5 |
NCT00572572 |
Aprepitant + 5HT3 + dexamethasone in patients with
germ cell tumours (there is significant increase in CR rate) |
IV |
6 |
NCT00659737 |
A randomized, double-blind comparison of oral
aprepitant alone versus oral aprepitant and transdermal scopolamine for
preventing postoperative nausea and vomiting |
II |
7 |
NCT00869310 |
Aprepitant in the prevention of cisplatin-induced
delayed emesis |
IV |
8 |
NCT00651755 |
Aprepitant effect on drug metabolism in multi-day
combination (CHOP/R-CHOP) chemotherapy regimen in lymphoma patients |
IV |
9 |
NCT00659945 |
Effectiveness of aprepitant in the treatment of
postoperative nausea and vomiting (PONV) in patients undergoing
outpatient plastic surgery |
III |
10 |
NCT01534637 |
Aprepitant in preventing nausea and vomiting in
patients undergoing chemotherapy and radiation therapy for pancreatic
cancer |
III |
11 |
NCT00415103 |
Aprepitant plus palonosetron versus granisetron in
the prevention of nausea and the emesis induced by chemotherapy in
patients treated with hematopoietic progenitors |
II |
12 |
NCT00734929 |
Aprepitant with dexamethasone versus ondansetron with
dexamethasone for postoperative nausea and vomiting (PONV) prophylaxis
in patients having craniotomy |
II |
13 |
NCT00869973 |
Aprepitant in the prevention of delayed emesis
induced by cyclophosphamide plus anthracyclines in breast cancer
Condition: nausea, vomiting |
II |
14 |
NCT00619359 |
Emesis Prevention of chemotherapy-induced nausea and
vomiting (CINV) associated with cisplatin chemotherapy noninferior |
II |
15 |
NCT00719173 |
Effect of aprepitant on cyclophosphamide
pharmacokinetics in patients with breast cancer |
II |
16 |
NCT00736073 |
A trial of aprepitant for prevention of
post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis |
II |
17 |
NCT00631930 |
Palonosetron, aprepitant, and low-dose dexamethasone
in preventing nausea and vomiting in patients undergoing high-dose
chemotherapy and stem cell transplant for multiple myeloma or lymphoma |
II |
18 |
NCT00895245 |
Fosaprepitant dimeglumine, palonosetron
hydrochloride, and dexamethasone in preventing nausea and vomiting
caused by cisplatin in patients with stage III or stage IV head and neck
cancer undergoing chemotherapy and radiation |
II |
19 |
NCT00293384 |
Aprepitant, granisetron, and dexamethasone in
preventing nausea and vomiting in patients receiving cyclophosphamide
before a stem cell transplant |
II |
20
|
NCT00314743
|
Oral neurokinin-1 antagonist, aprepitant, in combination with
ondansetron and
dexamethasone in patients undergoing autologous peripheral blood stem
cell
transplantation
|
IV
|
21
|
NCT00588835
|
Pharmacokinetic study on the addition of aprepitant to
cisplatin–etoposide treatment
in lung cancer patients
|
III
|
22 |
NCT00571168 |
Efficacy and safety of aprepitant in subjects with
multiple myeloma during and after high-dose chemotherapy |
III |
23 |
NCT00475085 |
Granisetron, dexamethasone, prochlorperazine,
aprepitant, and palonosetron in preventing nausea in women undergoing
chemotherapy for breast cancer |
III |
24
|
NCT00888329
|
Aprepitant for prevention of postoperative nausea and vomiting in
elective
hysterectomy Condition: postoperative nausea and vomiting
|
I
|
25 |
NCT00819039 |
A study of aprepitant (MK0869) in paediatric patients
undergoing surgery condition: postoperative nausea and vomiting |
I |
26
|
NCT00818259
|
Recruiting a study of aprepitant (MK0869) and fosaprepitant (MK0517) in
paediatric
patients receiving chemotherapy Condition: chemotherapy-induced nausea
and vomiting
|
II
|
27
|
NCT00896038
|
The effect of NK1R antagonism on alcohol craving and PTSD symptoms in
alcohol
dependent patients with PTSD Conditions: alcoholism; alcohol dependence;
post-traumatic stress disorder; FMRI
|
II
|